Biochemical aspects of Parkinson's disease

Neurology

Volumn 51, Issue 2 SUPPL., 1998, Pages

  Hornykiewicz, Oleh ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; MONOAMINE; NORADRENALIN; SEROTONIN;

BASAL GANGLION; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; GLOBUS PALLIDUS; HUMAN; HUMAN TISSUE; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STRIATE CORTEX; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

EID: 0031682676     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.51.2_suppl_2.s2     Document Type: Conference Paper

References (78)

1. Weber G. Zum Cholinesterasegehalt des Gehirns bei Hirntumoren und bei Parkinsonismus. Bull Schweiz Akad Med Wiss 1952;8:263-268.
2. Duvoisin RC. Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 1967;17:124-136.
3. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 1960;38:1236-1239.
4. Hornykiewicz O. From dopamine to Parkinson's disease: a personal research record. In: Samson F, Adelman G, eds. The neurosciences: paths of discovery II. Boston: Birkhäuser, 1992:125-146.
5. Hornykiewicz O. Levodopa in the 1960s: starting point Vienna. In: Poewe W, Lees AJ, eds. 20 Years of madopar - new avenues. Basel: Editiones Roche, 1994:11-27.
6. Bernheimer H, Hornykiewicz O. Herabgesetzte Konzentration der Homovanillinsäure im Gehirn von Parkinson-kranken Menschen als Ausdruck der Störung des zentralen Dopaminstoffwechsels. Klin Wochenschr 1965;43:711-715.
7. Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther 1975;195:453-464.
8. Zhong X-H, Haycock JW, Shannak K, et al. Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy. Mov Disord 1995;10:10-17.
9. 3H] cocaine binding to the dopamine transporter in Parkinson's disease. Eur J Pharmacol 1983;95: 145-146.
10. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996;47:718-726.
11. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973;20:415-455.
12. Fahn S, Libsch LR, Cutler RW. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci 1971;14:427-455.
13. Kish SJ, Shannak K, Hornykiewicz P. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880.
14. Nyberg P, Nordberg A, Wester P, Winblad B. Dopaminergic deficiency is more pronounced in putamen than in nucleus caudatus in Parkinson's disease. Neurochem Pathol 1983;1: 193-202.
15. Hassler R. Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol 1938; 48:387-476.
16. Gibb WRG, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:388-396.
17. Hornykiewicz O, Pifl Ch, Kish SJ, Shannak K, Schingnitz G. Biochemical changes in idiopathic Parkinson's disease, aging, and MPTP parkinsonism: similarities and differences. In: Calne DB, Comi G, Grippa D, Horowski R, Trabucchi, eds. Parkinsonism and aging. New York: Raven Press, 1989:57-67. [Aging series, vol. 32.]
18. Hornykiewicz O, Kish SJ, Rajput AH. Neurochemical aspects of Parkinson's disease and the dementing brain disorders: relation to brain ageing. In: Nagatsu T, Fisher A, Yoshida M, eds. Basic, clinical, and therapeutic aspects of Alzheimer's and Parkinson's diseases. Vol. 1. New York: Plenum Press, 1990: 445-452.
19. Crutcher MD, DeLong MR. Single cell studies of the primate putamen. I. Functional organization. Exp Brain Res 1984;53: 233-243.
20. Crutcher MD, DeLong MR. Single cell studies of the primate putamen. II. Relations to direction of movement and pattern of muscular activity. Exp Brain Res 1984;53:244-258.
21. Hornykiewicz O. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv Neurol 1993;60:140-147.
22. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 1978;273:59-61.
23. Birkmayer W, Hornykiewicz O. Der L-3,4-Dioxyphenylalanin (= L-DOPA)-Effekt bei der Parkinson-Akinesie. Wien Klin Wochenschr 1961;73:787-788.
24. Barbeau J, Sourkes TL, Murphy GF. Les catécholamines dans la maladie de Parkinson. In: de Ajuriaguerra J, ed. Monoamines et système nerveux central. Genève: George & Cie, 1962:247-262.
25. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276:374-379.
26. Perry TL, Javoy-Agid Y, Agid Y, Fibiger HC. Striatal GABAergic neuronal activity is not reduced in Parkinson's disease. J Neurochem 1983;40:1120-1123.
27. Kish SJ, Rajput A, Gilbert J, et al. Elevated γ-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss. Ann Neurol 1986;20:26-31.
28. Smith AD, Bolam JP. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 1990;13:259-265.
29. Shannak K, Rajput A, Rozdilsky B, Kish S, Gilbert J, Hornykiewicz O. Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects. Brain Res 1994;639:33-41.
30. Hornykiewicz O, Shannak K. Brain monoamines in progressive supranuclear palsy - comparison with idiopathic Parkinson's disease. J Neural Transm 1994;42(Suppl):219-227.
31. Hornykiewicz O. Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3-Hydroxytyramin) in der Substantia nigra des normalen und Parkinson-kranken Menschen. Wien Klin Wochenschr 1963;75:309-312.
32. Richfield EK, Young AB, Penney JB. Comparative distribution of dopamine D-1 and D-2 receptors in the basal ganglia of turtles, pigeons, rats, cats, and monkeys. J Comp Neurol 1987;262:446-463.
33. Mrzljak L, Bergson C, Pappy M, Huff R, Levenson R, Goldman-Rakic PS. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. Nature 1996;381: 245-248.
34. Johnson AE, Coirini H, Kallstrom L, Wiesel FA. Characterization of dopamine receptor binding sites in the subthalamic nucleus. Neuroreport 1994;5:1836-1838.
35. Yung KK, Bolam JP, Smith AD, Hersch SM, Ciliax BJ, Levey Al. Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 1995;65:709-730.
36. Bergstrom DA, Walters JR. Dopamine attenuates the effects of GABA on single unit activity in the globus pallidus. Brain Res 1984;310:23-33.
37. Wichmann T, Delong MR. Functional and pathopysiological models of the basal ganglia. Curr Opin Neurobiol 1996;6:751-758.
38. Ernst AM, Smelik PG. Site of action of dopamine and apomorphine on compulsive gnawing behaviour in rats. Experientia 1996;22:837.
39. Fletcher GH, Starr MS. Behavioural evidence for the functionality of D-2 but not D-1 dopamine receptors at multiple brain sites in the 6-hydroxy-dopamine-lesioned rat. Eur J Pharmacol 1987;138:407-411.
40. 2 agonists and antagonists injected into the nucleus accumbens and globus pallidus on jaw movements of rats. Eur J Pharmacol 1990;182:375-380.
41. Uhl GR, Hedreen JC, Prince DL. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 1985;35:1215-1218.
42. Moore RY, Bloom FE. Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. Annu Rev Neurosci 1978;1:129-169.
43. Price KS, Farley IJ, Hornykiewicz O. Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine. Adv Biochem Psychopharmacol 1978;19:293-300.
44. Mogenson GJ, Jones DL, Yim CY. From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol 1980;14:69-97.
45. 3) as a target for neuroleptics. Nature 1990; 347:146-151.
46. Heimer L, Zahm DS, Churchill L, Kalivas PW, Wohltmann C. Specificity in the projection patterns of accumbal core and shell in the rat. Neuroscience 1991;41:89-125.
47. Kish SJ, Chang LJ, Mirchandani L, Shannak K, Hornykiewicz O. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol 1985;18:530-536.
48. Riley DE, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology 1990;40:1203-1212.
49. Kish SJ, Gilbert JJ, Chang LJ, Mirchandani L, Shannak K, Hornykiewicz O. Brain neurotransmitter abnormalities in neuronal intranuclear inclusion body disorder. Ann Neurol 1985;17:405-407.
50. Gilbert JJ, Kish SJ, Chang LJ, Morito C, Shannak K, Hornykiewicz O. Dementia, parkinsonism, and motor neuron disease: neurochemical and neuropathological correlates. Ann Neurol 1988;24:688-691.
51. Brun A, Gottfries CG, Roos BE. Studies of the monoamine metabolism in the central nervous system in Jakob-Creutzfeldt disease. Acta Neurol Scand 1971;47:642-645.
52. Kanazawa I, Kwak S, Sasaki H, et al. Studies on neurotransmitter markers of the basal ganglia in Pick's disease, with special reference to dopamine reduction. J Neurol Sci 1988;83: 63-74.
53. Brücke T, Sofic E, Killian W, Rett A, Riederer P. Reduced concentrations and increased metabolism of biogenic amines in a single case of Rett syndrome: a postmortem brain study. J Neural Transm 1987;68:315-324.
54. Jankovic J, Kirpatrick JB, Blomquist KA, Langlais PJ, Bird ED. Late-onset Hallervorden-Spatz disease presenting as familial parkinsonism. Neurology 1985;35:227-234.
55. Narabayashi H. The neural mechanisms and progressive nature of symptoms of Parkinson's disease - based on clinical, neurophysiological and morphological studies. J Neural Transm [P-D Sect] 1995;10:63-75.
56. Bernheimer H, Birkmayer W, Hornykiewicz O. Zur Biochemie des Parkinson-Syndroms des Menschen. Einfluss der Monoaminoxydase-Hemmer-Therapie auf die Konzentration des Dopamins, Noradrenalins und 5-Hydroxytryptamins im Gehirn. Klin Wochenschr 1963;41:465-469.
57. Farley IJ, Hornykiewicz O. Noradrenaline in subcortical brain regions of patients with Parkinson's disease and control subjects. In: Birkmayer W, Hornykiewicz O, eds, Advances in parkinsonism. Basel: Roche, 1976:178-185.
58. Bernheimer H, Birkmayer W, Hornykiewicz O. Verteilung des 5-Hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinson-Syndrom. Klin Wochenschr 1961;39:1056-1059.
59. Agid Y, Javoy-Agid F. Peptides and Parkinson's disease. Trends Neurosci 1985;8:30-35.
60. Nisbet AP, Foster OJF, Kingsbury A, et al. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 1995;66:361-376.
61. Lloyd KG. Neurotransmitter interactions related to central dopamine neurons. In: Youdim MBH, Lovenberg W, Sharman DF, Lagnado JR, eds. Essays in neurochemistry and neuropharmacology. Chichester: John Wiley, 1977:131-207.
62. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1986;45;19-34.
63. von Buttlar-Brentano K. Das Parkinsonsyndrom im Lichte der lebensgeschichtlichen Veränderungen des Nucleus basalis. J Hirnforsch 1955;2:55-77.
64. Halliday GM, Li YW, Blumbergs PC, et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 1990;27:373-385.
65. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-4550.
66. Pifl Ch, Schingnitz G, Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 1991;44:591-605.
67. Hornykiewicz O, Pifl Ch. The validity of the MPTP primate model for the neurochemical pathology of idiopathic Parkinson's disease. In: Briley M, Marien M, eds. Noradrenergic mechanisms in Parkinson's disease. Boca Raton, FL: CRC Press, 1994:11-23.
68. Lloyd KG, Hornykiewicz O, Davidson L, et al. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Engl J Med 1981;305:1106-1111.
69. + within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiography study. Neuroscience 1991;40:133-158.
70. Lach B, Grimes D, Benoit B, Minkiewicz-Janda A. Caudate nucleus pathology in Parkinson's disease: ultrastructural and biochemical findings in biopsy material. Acta Neuropathol (Berl) 1992;83:352-360.
71. Uhl GR, Walther D, Mash D, Faucheux B, Javoy-Agid F. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol 1994;35: 494-498.
72. 2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J Comp Neurol 1995;362:400-410.
73. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985;82:2173-2177.
74. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 1996;16:436-447.
75. Le Couteur DG, Leighton PW, McCann SJ, Pond SM. Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease. Mov Disord 1997;12:760-763.
76. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994;344:796-798.
77. Schapira AHV. Neurotoxicity and the mechanisms of cell death in Parkinson's disease. Adv Neurol 1996;69:161-165.
78. Rajut AH, Fenton ME, Sitte H, Pifl C, Hornykiewicz O. Brain dopamine (DA) metabolism in dyskinesia and wearing off in idiopathic Parkinson's disease [Abstract]. Neurology 1998; 50(Suppl 4):A392-A393.